Core Viewpoint - The market anticipates Lemonade (LMND) to report flat earnings with a quarterly loss of $0.81 per share, while revenues are expected to increase by 33.1% to $162.39 million compared to the previous year [1][3]. Earnings Report Expectations - The earnings report is scheduled for August 5, and if the results exceed expectations, the stock may rise; conversely, missing estimates could lead to a decline [2]. - Management's discussion during the earnings call will significantly influence the stock's immediate price change and future earnings expectations [2]. Estimate Revisions - The consensus EPS estimate has been revised 1.67% higher in the last 30 days, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for Lemonade is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.40% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Lemonade currently holds a Zacks Rank of 2, suggesting a high likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Lemonade was expected to post a loss of $0.94 per share but actually reported a loss of -$0.86, resulting in a positive surprise of +8.51% [13]. - Over the past four quarters, Lemonade has consistently beaten consensus EPS estimates [14]. Conclusion - While an earnings beat may not solely dictate stock movement, betting on stocks expected to exceed earnings expectations can enhance the odds of success [15][16]. - Lemonade is viewed as a compelling candidate for an earnings beat, but investors should consider other influencing factors before making investment decisions [17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Revolve Group despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The earnings report is expected on August 5, with a consensus EPS estimate of $0.12, reflecting a -42.9% year-over-year change, while revenues are projected at $295.37 million, a 4.6% increase from the previous year [3][4]. Estimate Revisions - The consensus EPS estimate has been revised 20.59% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP for Revolve Group is +7.53%, suggesting a likelihood of beating the consensus EPS estimate, supported by a Zacks Rank of 2 [12]. Historical Performance - In the last reported quarter, Revolve Group exceeded the expected EPS of $0.13 by delivering $0.16, resulting in a +23.08% surprise. The company has beaten consensus EPS estimates in the last four quarters [13][14]. Industry Comparison - Columbia Sportswear, another player in the textile-apparel industry, is expected to report a loss of $0.28 per share, a -40% year-over-year change, with revenues projected at $589.48 million, a 3.4% increase [18].

Wall Street expects a year-over-year decline in earnings on higher revenues when ARS Pharmaceuticals, Inc. (SPRY) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Zacks Consensus Estimate This company is expected to post quarterly earnings of $1.39 per sh ...

Core Viewpoint - Stevanato Group (STVN) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on August 5, with a consensus estimate of quarterly earnings at $0.11 per share, reflecting a +10% year-over-year change [3]. - Revenues are projected to reach $302.83 million, representing an 8.4% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial projections during this period [4]. - The Most Accurate Estimate for Stevanato is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +20.93%, suggesting a bullish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Stevanato currently holds a Zacks Rank of 2, which, along with the positive Earnings ESP, suggests a high likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Stevanato exceeded the expected earnings of $0.10 per share, achieving actual earnings of $0.11, resulting in a surprise of +10% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14].

The consensus EPS estimate for the quarter has been revised 0.26% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Euroseas Ltd. (ESEA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actu ...

Core Viewpoint - The market anticipates Green Plains Renewable Energy (GPRE) to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - GPRE is expected to post a quarterly loss of $0.28 per share, reflecting a year-over-year change of +26.3%, while revenues are projected to be $592.3 million, down 4.3% from the previous year [3]. - The consensus EPS estimate has been revised 44.44% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent analyst revisions may provide more accurate predictions [8]. - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, with a historical success rate of nearly 70% for such combinations [10]. Current Analyst Sentiment - For GPRE, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.09%, indicating a bearish outlook from analysts [12]. - The stock currently holds a Zacks Rank of 3, complicating predictions for an earnings beat [12]. Historical Performance - In the last reported quarter, GPRE was expected to post a loss of $0.51 per share but actually reported a loss of -$0.88, resulting in a surprise of -72.55% [13]. - Over the past four quarters, GPRE has only beaten consensus EPS estimates once [14]. Conclusion - GPRE does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making decisions regarding the stock ahead of its earnings release [17].

Core Viewpoint - The market anticipates L.B. Foster (FSTR) to report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus EPS estimate for L.B. Foster is $0.52 per share, reflecting a 100% year-over-year increase, while revenues are projected at $144.26 million, a 2.5% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [4]. Earnings Surprise Prediction - The Most Accurate Estimate for L.B. Foster is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +12.62%, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, L.B. Foster was expected to post earnings of $0.01 per share but instead reported a loss of -$0.20, resulting in a surprise of -2,100.00% [13]. Over the last four quarters, the company has only beaten consensus EPS estimates once [14]. Investment Considerations - While an earnings beat may not solely dictate stock movement, betting on stocks expected to exceed earnings expectations can enhance the odds of success [15][16]. L.B. Foster is viewed as a compelling earnings-beat candidate, but investors should consider other influencing factors [17].

Henry Schein (HSIC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 5, might help the stock move higher if these key numbers are better than expectati ...

Core Viewpoint - Karyopharm Therapeutics (KPTI) is expected to report a year-over-year decline in earnings and revenues for the quarter ended June 2025, with the consensus outlook indicating a loss of $3.80 per share and revenues of $40.08 million, reflecting a 26.7% and 6.3% decrease respectively [1][3]. Earnings Expectations - The upcoming earnings report could lead to a stock price increase if the actual results exceed expectations, while a miss could result in a decline [2]. - The consensus EPS estimate has been revised 2.21% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that Karyopharm has a positive Earnings ESP of +0.92%, indicating a likelihood of beating the consensus EPS estimate [12]. - The stock currently holds a Zacks Rank of 3, which supports the potential for an earnings beat [12]. Historical Performance - Karyopharm has a history of exceeding consensus EPS estimates, having beaten expectations in the last four quarters [14]. - In the last reported quarter, the company was expected to post a loss of $4.21 per share but actually reported a loss of -$2.77, resulting in a positive surprise of +34.20% [13]. Industry Context - In the Zacks Medical - Drugs industry, Ardelyx (ARDX) is expected to report a loss of $0.13 per share, indicating a significant year-over-year decline of 85.7%, with revenues projected at $84.64 million, up 15.6% from the previous year [18]. - Ardelyx's consensus EPS estimate has been revised 6.3% lower, resulting in a negative Earnings ESP of -6.18%, combined with a Zacks Rank of 4, making it difficult to predict an earnings beat [19].